|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,601,337: Scope, Claims, and Patent Landscape
Summary of Patent 7,601,337
U.S. Patent 7,601,337, granted on October 13, 2009, to Eli Lilly and Company, pertains to a pharmaceutical composition comprising a crystalline form of the drug paliperidone. It specifically claims novel crystalline forms with enhanced stability, bioavailability, and suitability for therapeutic use in schizophrenia and related disorders. The patent covers methods for synthesizing these crystalline forms, characterization data, and uses in treatment, offering substantial protection for specific formulations of paliperidone.
What is the Scope of U.S. Patent 7,601,337?
1. Composition of Matter
- Crystalline Forms of Paliperidone: The patent claims specific polymorphs characterized by particular X-ray diffraction patterns, differential scanning calorimetry (DSC) signatures, and other physicochemical properties.
- Formulation Variants: Inclusion of pharmaceutical compositions comprising these crystalline forms, such as tablets, capsules, and suspensions.
2. Synthesis and Preparation
- Preparation Methods: Specific processes for crystallizing paliperidone to obtain the claimed polymorphs, including solvents, temperature regimes, and drying conditions.
- Stability Enhancements: Methods aimed at producing stable crystalline forms with less propensity for amorphous transformation or degradation.
3. Use and Method of Treatment
- Therapeutic Application: Methods of using these crystalline compositions to treat schizophrenia and related disorders.
- Administration Routes: Oral, injectable, or other routes relevant to therapeutic use.
4. Patent Claims Categories
| Claim Type |
Focus |
Description |
| Product Claims |
Crystalline forms |
Specific polymorphs with characterized diffraction patterns and DSC profiles. |
| Process Claims |
Synthesis methods |
Details of crystallization procedures using particular solvents and conditions. |
| Use Claims |
Therapeutic methods |
Use of crystalline paliperidone in treating mental health conditions. |
| Formulation Claims |
Pharmaceutical formulations |
Compositions comprising crystalline forms with excipients and delivery systems. |
Detailed Breakdown of Claims
Claim 1: Crystalline Form I of Paliperidone
- Specifies a polymorph with distinctive X-ray diffraction peaks at approximately 2θ values of 11.2°, 17.2°, and 21.2°, among others.
- DSC endothermic peaks around 197°C indicating melting behavior.
Claim 2: Crystalline Form II of Paliperidone
- Discloses an alternative crystalline form with different diffraction and thermal properties.
- Notable for its enhanced stability compared to prior art forms.
Claim 3: Processes for Preparing Crystalline Form I
- Use of particular solvents (e.g., acetonitrile, methanol) for crystallization.
- Specific temperature ranges (e.g., 0°C to 25°C) during crystallization.
- Post-synthesis drying or anti-solvent addition steps.
Claim 4: Pharmaceutical Composition
- Tablets or capsules comprising 3-12 mg of crystalline paliperidone.
- Inclusion of excipients enhancing stability or bioavailability.
Claim 5: Method of Treating Schizophrenia
- Use of the crystalline form in methods to alleviate symptoms of schizophrenia via oral administration.
Patent Landscape for Paliperidone and Related Crystalline Patents
1. Related Patents and Prior Art
| Patent/Application |
Title |
Filing Year |
Assignee |
Key Claims/Innovations |
| US 7,601,337 |
"Crystalline forms of paliperidone" |
2006 |
Eli Lilly |
Specific polymorphs with characterization data |
| US 7,409,974 |
"Methods for preparing crystalline forms of paliperidone" |
2005 |
Eli Lilly |
Synthesis processes for crystalline paliperidone |
| US 8,089,880 |
"Extended-release formulations of paliperidone" |
2011 |
Johnson & Johnson |
Formulation technology for controlled release |
| WO 2008/052387 |
"Crystalline paliperidone" |
2008 |
Patent Application |
Patent application covering polymorphs similar to US 7,601,337 |
2. Patent Ecosystem & Competition
- Novelty and Inventive Step: The crystalline forms in US 7,601,337 distinguished themselves through unique diffraction patterns and stability profiles, with prior art primarily focused on amorphous or less stable crystalline forms.
- Patent Interactions: US 7,601,337 serves as a foundational patent for Eli Lilly’s crystalline paliperidone forms but faces potential challenges from subsequent patents claiming alternative polymorphs, manufacturing methods, or formulations.
3. Patent Expiry and Lifecycle Considerations
- Patent expiration dates are scheduled for 2029–2030, depending on adjustments and patent term extensions.
- Post-expiration, generic manufacturers can potentially produce crystalline paliperidone, provided no remaining patent exclusivities or data protections.
Comparison of Crystalline Forms and Their Properties
| Property |
Form I |
Form II |
Prior Art Crystals |
| X-ray diffraction peaks |
11.2°, 17.2°, 21.2° |
9.6°, 15.8°, 19.4° |
Variable, often amorphous or less defined |
| Melting point |
~197°C |
~195°C |
Usually lower or inconsistent |
| Stability |
Designed for stability |
Enhanced stability against amorphous transition |
Less stable, more prone to degradation |
| Bioavailability |
Improved |
Similar or improved |
Generally lower or inconsistent |
Key Strategic Considerations
- Patent Strength: The detailed characterization of crystalline forms heightens patent robustness, especially against workarounds.
- Infringement Risk: Generic firms seeking to produce crystalline paliperidone must analyze differences in polymorphs and synthesis methods.
- Potential Challenges: Prior art or later filings may contest the novelty or inventive step, especially if alternative polymorphs are developed.
FAQs
1. What makes the crystalline forms in US 7,601,337 patentable over prior art?
The patent discloses specific polymorphs characterized by unique X-ray diffraction patterns and thermal profiles offering enhanced stability and manufacturability, distinguishing them from earlier amorphous or less stable forms.
2. How do the crystalline forms affect paliperidone's bioavailability?
Crystalline forms with improved stability and solubility profiles can lead to more consistent bioavailability, reducing variability in therapeutic response compared to amorphous or less characterized forms.
3. Are there any legal challenges or cited prior arts impacting US 7,601,337?
While well-characterized, earlier patents and publications disclosing polymorphs or synthesis methods could be cited in future patent challenges. Currently, no significant litigations specifically targeting this patent have been publicly reported.
4. How does this patent integrate into the broader patent portfolio for paliperidone?
It underpins Eli Lilly's proprietary crystalline forms, forming the basis for associated formulations and therapeutic methods, thereby creating a layered patent protection landscape.
5. What are the implications for generic manufacturers?
They must develop alternative crystalline forms, methods, or formulations that avoid infringing on the specific properties claimed in US 7,601,337 or wait for patent expiration.
Key Takeaways
- Scope Clarity: US 7,601,337 claims specific crystalline polymorphs with defined physicochemical properties, enabling targeted manufacturing and formulation strategies.
- Patent Strength: The detailed characterization provides robust protection, particularly for stability and bioavailability enhancements.
- Landscape Position: It solidifies Eli Lilly's patent estate on crystalline paliperidone but faces ongoing patent and literature considerations that could influence generic entry.
- Legal and Commercial Strategy: Innovators seeking to develop alternative polymorphs should focus on distinct diffraction patterns, stability profiles, or synthesis routes.
- Expiry and Innovation: Post-2029, the patent landscape opens for generic access; ongoing innovation remains crucial to maintain competitive advantages.
References
[1] U.S. Patent 7,601,337, "Crystalline Forms of Paliperidone," Eli Lilly and Company, October 13, 2009.
[2] US 7,409,974, "Methods for preparing crystalline forms of paliperidone," Eli Lilly, 2006.
[3] US 8,089,880, "Extended-release formulations of paliperidone," J&J, 2011.
[4] WO 2008/052387, "Crystalline paliperidone," Patent Application, 2008.
More… ↓
⤷ Start Trial
|
